Evaluation of the Sensitivity and Specificity of a Novel Quality of Life Tool to Assess the Treatment Satisfaction in Psoriasis Patients
- Conditions
- Psoriasis
- Interventions
- Other: DLQI and PSO-TARGET QoL grid
- Registration Number
- NCT04765332
- Lead Sponsor
- Clinact
- Brief Summary
The severity of psoriasis can be influenced by a great variety of factors including extent of the disease, lesions location and impact on quality of life. The current standard of care for psoriasis is focusing on the reduction of the skin symptoms as defined by the PASI, somewhat setting asides the patient's feelings in terms of which aspects of his/her life are affected by the disease. Despite the fact that multiple patient reported outcomes (PRO) questionnaires are available to evaluate the impact of the disease on patients' quality of life, only few items address the subjective impact of skin disease. Among the available PROs the Dermatology Life Quality Index (DLQI) is the most frequently used. It is a standardized tool designed to cover a broad range of dermatologic afflictions but lacks specificity towards the effect of psoriasis on quality of life. The DLQI is composed of ten questions grouped in 6 domains "symptoms and feelings", "daily activities", "leisure", "work/school", "personal relationships" and "treatment". Each answer is graded from 0 to 3. The DLQI score is calculated by adding the score of each question, resulting in a maximum score of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
Because of its limitations, some patients cannot seem to completely restore a normal quality of life (e.g. DLQI 0-1) even though their reached a perfect PASI score (100). This phenomenon may be explained by the fact that the patient's own perception can be different from the physician's perspective and may have changed in time, between follow-ups. These are as many reasons as why it is highly difficult to accurately fathom the therapeutic expectations of the psoriasis patients. The standard tools currently in use are not able to assess the perception of the disease by the patient its evolution over time. In addition, it is widely recognized that alexithymia is more prevalent in the psoriasis patients than in the general population and patients with alexithymia appear to suffer higher psoriasis burden as they have more difficulties to express their expectations. Since patients struggle to recognize and verbalize their emotions, it can be useful and informative to offer patients a variety of verbatim in which they can identify. PSO-TARGET is an exploratory observational, non-interventional study aiming to evaluate a novel approach of assessing psoriasis patients' satisfaction towards their biologic treatment from a quality of life standpoint by using a psoriasis-specific Quality of Life assessment grid.
The aim of this exploratory study is to evaluate the sensitivity and specificity of the PSO-TARGET QoL Component grid as part of a new approach for assessing the level of achievement of the psoriasis patient's therapeutic goal, identified by himself, after a treatment with Kyntheum®.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 143
- Age > 18 years
- Patient for whom the dermatologist decided to initiate a treatment by Kyntheum® according to SmPC.
- Patient who signed an informed consent
-
Vulnerable subjects according to the law;
- pregnant, parturient or breast feeding women;
- deprived of their freedom by administrative, medical or legal decision or who is under trusteeship/guardianship;
- legally protected, or unable to express their consent to participate;
- With no affiliation to a social security system;
-
Psychologically/linguistically unable to express their consent to participate
-
With an hypersensitivity to at least one of the excipients of Kyntheum®
-
Participating at the same time in another clinical trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Included patients DLQI and PSO-TARGET QoL grid Fill patient questionnaires at inclusion visit, around 3 months and 12 months
- Primary Outcome Measures
Name Time Method Level of concordance between the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid and the DLQI in assessing the impact of the treatment on the patients' quality of life. At first follow-up visit (around 12 weeks)
- Secondary Outcome Measures
Name Time Method Research of predictive factors (among baseline characteristics) of the achievement of the main treatment goal. At first follow-up visit (around 12 weeks) Percentage of agreement between the physician-reported and the patient-reported dimensions At first follow-up visit (around 12 weeks) The percentage of patients who achieved the main treatment goal identified by the patient himself in the QoL component grid at baseline. At first follow-up visit (around 12 weeks) The therapeutic objective achievement is defined as "satisfied" or "very satisfied" response on 4 points Likert scale.
Level of concordance between the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid and the DLQI At last follow up (around 52 weeks) Rate of patients having changed objective at the 1st follow-up visit At first follow-up visit (around 12 weeks) Level of accordance between PASI 90/100 and the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid. at the 2nd follow-up visit (around 52 weeks) Percentage of patients who have maintained at 52 ± 4 weeks the level of satisfaction achieved at the 1st follow-up visit. At last follow up (around 52 weeks) Psoriasis Area and Severity Index (PASI) at the 2nd follow-up visit (around 52 weeks.). Calculation of the percentage of skin surface area affected. Estimation of how many hands surface (palm + fingers) of the patient correspond to psoriatic lesions. one hand surface is considered as 1% of total body skin surface
Dermatology Life Quality Index (DLQI Scores) at the 2nd follow-up visit (around 52 weeks) Patient questionnaire, score is calculated between 0 (worst score possible) and 30 (best score possible)
Trial Locations
- Locations (23)
CHU de CAEN
🇫🇷Caen, France
Ch de Perpignan
🇫🇷Perpignan, France
Private practice
🇧🇪Waregem, Belgium
CHU Ambroise Paré
🇧🇪Mons, Belgium
Cliniques Universitaires Saint Luc - UCLouvain
🇧🇪Bruxelles, Belgium
Centre Dermatologique du Roy
🇧🇪Lasne, Belgium
Dermatology Maldegem
🇧🇪Maldegem, Belgium
CHU UCL Namur - Sainte Elisabeth
🇧🇪Namur, Belgium
Polyclinique de Courlancy-Bezanes
🇫🇷Bezannes, France
Chu de Rennes
🇫🇷Auray, France
Centre Hospitalier de Boulogne-sur-mer
🇫🇷Boulogne-sur-Mer, France
Chru de Besancon - Hopital Jean Minjoz
🇫🇷Besançon, France
Hopital Jacques Monod
🇫🇷Montivilliers, France
Nouvel Hôpital Sud Francilien
🇫🇷Corbeil-Essonnes, France
Ch William Morey
🇫🇷Chalon-sur-Saône, France
Cide Azur
🇫🇷Nice, France
Hopital Paris Saint-Joseph
🇫🇷Paris, France
Ch Cote de Lumiere
🇫🇷Olonne-sur-Mer, France
Hôpital d'Instruction des armées SAINTE ANNE
🇫🇷Toulon, France
Hopital Larrey
🇫🇷Toulouse, France
CHU de Poitiers
🇫🇷Poitiers, France
Ch Annecy Genevois
🇫🇷Épagny, France
CHRU de NANCY - BSM BRABOIS
🇫🇷Vandœuvre-lès-Nancy, France